Salute e Benessere
Accelerating Drug Discovery: Tsingke Biotech Unveils Next-Generation Rapid Protein and Antibody Solutions
Tsingke Biotech combines to deliver . The company supports —including E. coli, Bacillus subtilis, yeast, insect, mammalian, and cell-free systems—allowing simple proteins to be produced in , while complex proteins and antibodies are ready in . According to Tsingke, overall protein expression
Traditional hybridoma-based antibody development can take 1–2 months. preserves natural pairing and generates high-affinity antibodies , . The service is engineered for efficiency, delivering full, comprehensive results in a remarkable timeframe of just . Furthermore, the supported formats encompass a broad spectrum of sourced from both mouse and rabbit models, ensuring versatility for critical research and development needs.
In addition, for antibody production, Tsingke uses and systems, achieving and , with . A broad range of antibody formats, including and , are available.
Tsingke Biotech's booth at the PEGS Summit attracted attention from global biopharma professionals, with many visitors engaging in discussions and companies exploring potential collaborations. This reflects the growing demand for innovative solutions in protein and antibody production.
"PEGS is a key event for protein and antibody engineering," said
Nan Zhang , Global Marketing Manager at Tsingke Biotech. "Our service's combination of
is designed to help the biopharma industry meet the growing demand for
."
Tsingke's subsidiary operates with state-of-the-art , ensuring high standards of quality and a smooth transition from research-grade to .
Beijing Tsingke Biotech Co., Ltd. is a leading biotechnology company that provides comprehensive solutions for research and therapeutic development. With expertise in molecular biology, genetics, and protein science, Tsingke offers custom DNA/RNA synthesis, gene cloning, protein expression, antibody discovery, and viral vector packaging (AAV, LV, AdV). Its production environments, certified with ISO 13485 and Class 100,000 cleanrooms, ensure consistent quality and reliability. Backed by advanced automation and a global scientific team, Tsingke accelerates innovation in drug discovery, functional genomics, and genetic engineering, thereby empowering researchers worldwide with cutting-edge biomanufacturing solutions.
For news and updates, follow Tsingke Biotech on LinkedIn .
info@tsingke.com.cn
Photo - https://mma.prnewswire.com/media/2827171/Tsingke_Biotech_s_Overseas_BD_team_booth_engages_strategic_discussions_biopharma.jpg
View original content:https://www.prnewswire.co.uk/news-releases/accelerating-drug-discovery-tsingke-biotech-unveils-next-generation-rapid-protein-and-antibody-solutions-302620110.html